ALKS
Alkermes Plc
ACTIONABLEMethodology gates passed
Position levels
Currenttoday
USD 49.17
Buy <=wait / entry
USD 38.67
Trim >=take some off
USD 52.00
Thesis breakA material adverse change in the Avadel synergy outlook, a LUMRYZ franchise grow...
-
Scenario-weighted conviction
| Probability | Score | Contribution | |
|---|---|---|---|
| Bull case | 19% | 100 / 100 | 19.0 |
| Base case | 50% | 62 / 100 | 31.0 |
| Bear case | 31% | 10 / 100 | 3.1 |
| Weighted conviction | 53 / 100 - OPPORTUNISTIC BUY | ||
Top risks
- M&A activity: Completed acquisition of Avadel Pharmaceuticals plc, expected to be accretive in 2026
- Earnings and guidance changes: Reported Q4 2025 and Q1 2026 financial results with 2026 expectations provided
- Strategic licensing or supply agreements: Multiyear manufacturing agreement generating $15-20M annual revenue (historical but evidenced)